New Drugs for Gout and Ulcerative Colitis
New drugs for gout and ulcerative colitis, two diseases that plague millions of people worldwide have been found.
Identifying the Signs of Breast Cancer
The early stages of breast cancer may not have any symptoms. That is why you must learn how to identify the signs of breast cancer before it's too late!
Full Body Detox
Lose 10 - 50lbs in 3 week with detox!
Do I Have Healthy Prostate Gland?
Don't wait until it's too late! Make sure you have healthy prostate gland.

Thursday, September 15, 2005

Abbott's prostate cancer drug, Xinlay, turned down by FDA panel

In what is seen as a serious setback for Abbott Laboratories, the Oncology Drug Advisory Committee (ODAC) to the US Food and Drug Administration (FDA) advised against the approval of Xinlay (atrasentan), an experimental drug for prostate cancer. Abbott was hoping Xinlay would become a blockbuster (big-selling drug). The panel were concerned about lack of clear efficacy evidence, they also wondered about its cardiovascular safety.

The panel, in its report, mentioned some protocol violations.

Abbot disagreed, saying the benefits are great while the safety profile is manageable.

Abbott says it is hopeful the FDA's final decision may be different. Historically, the agency tends to go by what the panel has recommended.

Read more: Abbott's prostate cancer drug, Xinlay, turned down by FDA panel


Post a Comment

<< Home